Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV000560514 | SCV000653743 | likely pathogenic | Axenfeld-Rieger syndrome type 1; Anterior segment dysgenesis 4 | 2016-10-27 | criteria provided, single submitter | clinical testing | This variant is expected to disrupt the functionally conserved OAR or aristaless domain, which is located in the final 39 amino acids of the PITX2 protein. This domain mediates the interaction with a number of proteins that are required for PITX2 transcriptional transactivation activity (PMID: 10490637, 18045789, 15728254). In addition, a different variant affecting this splice acceptor site (c.253-1G>A) has been reported in 2 individuals affected with Axenfeld-Rieger syndrome (PMID: 22569110). This suggests that this splice site is critical for PITX2 protein function, and that other variants that affect this splice site may also be pathogenic. In summary, this variant is a novel splice site variant that is expected to disrupt an important protein binding domain. This evidence indicates that the variant is pathogenic, but additional data is needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant has not been reported in the literature in individuals with a PITX2-related disease. This sequence change affects an acceptor splice site in the last intron (intron 4) of the PITX2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 187 amino acids of the PITX2 protein. |
| Human Developmental Genetics Laboratory, |
RCV002293457 | SCV002538930 | pathogenic | Axenfeld-Rieger syndrome type 1 | 2022-06-23 | criteria provided, single submitter | research |